Action: HR 4215 recently introduced!
A bipartisan bill (HR 4215) to address Medicare reimbursement of HCT was introduced on Thursday, November 2nd by Representatives Erik Paulsen (MN-03), Doris Matsui (CA-06), Gus Bilirakis (FL-12), and Ron Kind (WI-03). Currently, Medicare reimbursement for allogeneic HCT under MS-DRG 014 is approximately $65,000, leaving transplant centers with very few dollars, if any, to cover a patient’s inpatient stay as well as donor search and cell acquisition costs. This legislation would require the Centers for Medicare & Medicaid Services (CMS) to reimburse hospitals for donor search and cell acquisition costs on a reasonable basis and separate from the current MS-DRG 014 payment.
We need your help to advocate for this critical legislation that will improve Medicare reimbursement and help protect your patients’ access to HCT. Please ask your Members of Congress to support HR 4215 today!
Watch for more information about how you can get involved, bill status and next steps over the coming weeks, and feel free to contact us with any questions.